Přehled o publikaci
2024
Metabolic Syndrome Prevalence in Women with Gestational Diabetes Mellitus in the Second Trimester of Gravidity
BARTÁKOVÁ, Vendula, Katarína CHALÁSOVÁ, Lukáš PÁCAL, Veronika ŤÁPALOVÁ, Jan MÁCHAL et. al.Základní údaje
Originální název
Metabolic Syndrome Prevalence in Women with Gestational Diabetes Mellitus in the Second Trimester of Gravidity
Autoři
BARTÁKOVÁ, Vendula, Katarína CHALÁSOVÁ, Lukáš PÁCAL, Veronika ŤÁPALOVÁ, Jan MÁCHAL, Petr JANKŮ a Kateřina KAŇKOVÁ
Vydání
JOURNAL OF CLINICAL MEDICINE, SWITZERLAND, MDPI, 2024, 2077-0383
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Organizace
Lékařská fakulta – Masarykova univerzita – Repozitář
UT WoS
999
EID Scopus
999
Klíčová slova anglicky
gestational diabetes; metabolic syndrome; pregnancy; obesity
Návaznosti
LX22NPO5104, projekt VaV.
Změněno: 19. 4. 2024 03:52, RNDr. Daniel Jakubík
Anotace
V originále
Background: Women with gestational diabetes (GDM) have an increased risk of metabolic syndrome (MS) after delivery. MS could precede gravidity. The aims of this study were (i) to detect the prevalence of MS in women at the time of GDM diagnosis, (ii) to detect the prevalence of MS in the subgroup of GDM patients with any form of impaired glucose tolerance after delivery (PGI), and (iii) to determine whether GDM women with MS have a higher risk of peripartal adverse outcomes. Methods: A cross-sectional observational study comprised n = 455 women with GDM. International Diabetes Federation (IDF) criteria for MS definition were modified to the pregnancy situation. Results: MS was detected in 22.6% of GDM patients in those with PGI 40%. The presence of MS in GDM patients was associated with two peripartal outcomes: higher incidence of pathologic Apgar score and macrosomia (p = 0.01 resp. p = 0.0004, chi-square). Conclusions: The presence of MS in GDM patients is a statistically significant risk factor (p = 0.04 chi-square) for PGI. A strong clinical implication of our findings might be to include MS diagnostics within GDM screening using modified MS criteria in the second trimester of pregnancy.